9^th World Biomarkers Congress

Cancer remains one of the most lethal diseases for human. In recent studies, we performed whole genome analysis on prostate and liver cancers. Our result showed that combination of genome copy number variance, genome methylation pattern and novel fusion transcripts specifi c for cancer achieved high accuracy in predicting clinical outcomes of these cancers. Interestingly, some of these fusion genes are also present in a variety of human malignancies. Some of these fusion gene products trigger new pathways that are essential for carcinogenesis in multiple human cancers, and create novel functions that are not present in wild type gene counterparts. Some of these novel fusion genes are highly targetable and treatment of cancers with drugs specifi c for these genes and their signaling pathways produced dramatic improvement of metastasis and survival rate of animals xenograft ed with cancers positive for these fusion genes.Our analyses suggest that targeting therapy for fusion genes holds promise as an eff ective treatment for human cancers.